16 December 2020, London. EMMAC Life Sciences Group (“EMMAC” or the “Group” or the “Company”), Europe’s largest independent cannabis company, is pleased to announce that it has raised £15.0 million via an issue of Convertible Loan Notes (the “CLN Issue”). The CLN Issue saw strong support from existing shareholders, with Measure 8 Venture Partners LP, EMMAC’s largest existing cash investor, leading the round with a significant investment.
EMMAC continues to build upon its leading position as Europe’s largest independent cannabis company and is seeing growth in its key markets in Europe as the demand for premium medical cannabis and wellness products grows. The UK medical cannabis market in particular is witnessing significant momentum, with EMMAC leading the way in enabling greater patient access in terms of product accessibility and cost for patients.
Antonio Costanzo, CEO of EMMAC, said: “We are pleased to see strong interest in this round of funding, which will allow EMMAC to continue to scale and build on its position as the European leader. I would like to take the opportunity to thank Measure 8 for its support leading this funding round and to all shareholders for their support as we grow a robust and sustainable business.”
About EMMAC Life Sciences Group
EMMAC Life Sciences Group is Europe’s largest independent cannabis company, bringing together pioneering science and research with cutting-edge cultivation, extraction and production. With a unique supply and distribution network throughout Europe, EMMAC’s vision is to bring the life-enhancing potential of cannabis to the people who need it.
For scientific enquiries please contact email@example.com
For general enquiries please contact firstname.lastname@example.org or visit www.emmac.com
Henry Harrison-Topham / Jamie Hooper / Ariadna Peretz
All statements, other than statements of historical fact, in this news release are forward-looking statements that involve various risks and uncertainties, including, without limitation, statements regarding potential values, the future plans and objectives of EMMAC Life Sciences Group. There can be no assurance that such statements will prove to be accurate, achievable or recognisable in the near term.
Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. EMMAC Life Sciences Group assumes no obligation to update forward-looking statements should circumstances or management’s estimates or opinions change.